Loading...
•
Dec 31, 2024
•/
Valneva Q4 2024 Earnings Report
Valneva reported Q4 2024 results, swinging to a net loss with sequential revenue growth driven by IXIARO and IXCHIQ sales.
Key Takeaways
Valneva posted €53 million in revenue for Q4 2024, but recorded a net loss of €36.9 million, impacted by higher R&D and finance expenses. Despite robust vaccine sales, profitability deteriorated from prior quarters.
Q4 revenue reached approximately €53 million.
Net loss of €36.9 million in the quarter, reversing prior profitability.
Strong contributions from IXIARO and first-time IXCHIQ sales.
Increased R&D and finance costs weighed heavily on results.
Revenue by Segment
Revenue by Geographic Location
Forward Guidance
Valneva expects continued sales growth in travel vaccines and strong momentum in the launch of IXCHIQ while focusing on R&D pipeline advancement.
Positive Outlook
- Solid demand for IXIARO and DUKORAL expected to continue.
- Full-year profitability targeted for 2025.
- Further regulatory submissions for IXCHIQ planned.
- Strategic partnerships expected to enhance pipeline progress.
- Continued support from CEPI and EU for vaccine development.
Challenges Ahead
- High R&D expenses will continue to impact short-term earnings.
- Potential FX headwinds from USD and SEK fluctuations.
- Competition in travel vaccines could pressure pricing.
- Uncertainties regarding Lyme disease vaccine commercialization timing.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...